Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Ascaso
Juan F
JF
Endocrinology Service, Clinic University Hospital, University of Valencia, Spain.
Fernández-Cruz
Arturo
A
González Santos
Pedro
P
Hernández Mijares
Antonio
A
Mangas Rojas
Alipio
A
Millán
Jesus
J
Felipe Pallardo
Luis
L
Pedro-Botet
Juan
J
Pérez-Jiménez
Francisco
F
Pía
Gonzalo
G
Pintó
Xavier
X
Plaza
Ignacio
I
Rubiés-Prat
Juan
J
D001629:Bezafibrate / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood*; D011345:Fenofibrate / Q000627:therapeutic use; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000097:blood / Q000517:prevention & control*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009525:Niacin / Q000627:therapeutic use; D018570:Risk Assessment
D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D002784:Cholesterol; D015248:Gemfibrozil; D011345:Fenofibrate; D001629:Bezafibrate